Latest Pharma and Biotech News
Pharmaceutical
28 January 2025 The headline payment percentage for newer medicines under the Voluntary Scheme for Branded Medicines Pricing and Access (VPAG) has been set at 22.9% for 2025, raising concerns from the UK pharma industry.
Today's issue
Refine Search
Pharmaceutical
Newly-launched obesity company Kailera Therapeutics has announced the appointment of Jamie Coleman as chief commercial officer (CCO). 28 January 2025
Pharmaceutical
Privately-held Isotope Technologies Munich (ITM) has presented attention-grabbing positive Phase III results from a radiopharmaceutical clinical trial. 28 January 2025
Pharmaceutical
Massachusetts-based radiopharmaceutical company Lantheus has announced its plans to acquire clinical-stage radiopharma developer Evergreen Theragnostics in a deal worth up to $1 billion. 28 January 2025
Pharmaceutical
The US Food and Drug Administration (FDA) has named Sara Brenner, a physician and senior official in its medical device division, as acting Commissioner. 28 January 2025
Biotechnology
Cambridge, USA-based biotech Sage Therapeutics yesterday announced that, while rejecting an unsolicited takeover offer, its board of directors has initiated a process to explore strategic alternatives for the company. 28 January 2025
Pharmaceutical
USA-based Neurocrine Biosciences yesterday revealed it has amended its agreement with Japanese pharma major Takeda to develop and commercialize osavampator (NBI-1065845/TAK-653). 28 January 2025
Biotechnology
The biotech IPO landscape gains momentum in 2025 as Aurion Biotech, Maze Therapeutics, and Metsera file for offerings. 28 January 2025
Pharmaceutical
The headline payment percentage for newer medicines under the Voluntary Scheme for Branded Medicines Pricing and Access (VPAG) has been set at 22.9% for 2025, raising concerns from the UK pharma industry. 28 January 2025
Biotechnology
Boston, USA-based RNA focused biotech Atalanta Therapeutics today announced the completion of a $97 million Series B financing to support Phase I clinical trials of the company’s investigational RNAi therapies for KCNT1-related epilepsy and Huntington’s disease. 28 January 2025
Biotechnology
AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the USA as the first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease progression after one or more endocrine therapies. 28 January 2025
Biotechnology
Shares in Swiss pharma giant Roche were more than 1% higher on Tuesday afternoon, following the announcement of positive top-line results from the overall survival (OS) analysis of the Phase III INAVO120 study. 28 January 2025
Biotechnology
US clinical-stage liver disease focused biotech Akero Therapeutics saw its shares almost double to $51.71 yesterday, after it released positive preliminary top-line week 96 results from SYMMETRY. 28 January 2025
Biotechnology
Boston, USA-based biotech Averna Therapeutics (formerly known as Exsilio Therapeutics), revealed yesterday that it has appointed Thomas Barnes as its chief executive (CEO) and director. 28 January 2025
Pharmaceutical
The US Food and Drug Administration (FDA) has accepted for priority review a supplemental new drug application (sNDA) for Welireg (belzutifan), Merck & Co’s oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor. 28 January 2025
Biotechnology
California, USA-based biotech Allakos saw its shares plummet 78.8% to $0.26 yesterday, after it announced disappointing top-line results from its Phase I clinical trial of AK006 in chronic spontaneous urticaria (CSU). 28 January 2025
Pharmaceutical
Taiho Oncology has presented real-world data highlighting the benefits of combining Lonsurf (trifluridine/tipiracil) with bevacizumab for metastatic colorectal cancer. 27 January 2025
Biotechnology
Results have been announced from a Phase III trial of Merck & Co’s anti-PD-1 therapy Keytruda (pembrolizumab) plus Lenvima (lenvatinib), Eisai’s orally available multiple receptor tyrosine kinase inhibitor (TKI), alongside chemotherapy, as a first-line treatment of locally-advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastroesophageal adenocarcinoma. 27 January 2025
Biotechnology
Akeso has announced that its new drug application for gumokimab, an IL-17-targeting monoclonal antibody, has been accepted in China. 27 January 2025
Biotechnology
Eisai and Biogen have secured US Food and Drug Administration approval for a once-monthly intravenous maintenance dosing regimen for Leqembi (lecanemab). 27 January 2025
Pharmaceutical
Obesity-focused Aardvark Therapeutics is hoping to raise $100 million in an initial public offering (IPO), according to a US Securities and Exchange Commission (SEC) filing. 27 January 2025
All news
Pharmaceutical
Disgraced drugmaker Purdue Pharma and its owners, the Sackler family, have agreed to a $7.4 billion settlement to address their role in the US opioid crisis. 24 January 2025
Pharmaceutical
Vigil Neuroscience has announced plans to advance its oral TREM2 agonist, VG-3927, into Phase II trials for Alzheimer’s disease this year. 24 January 2025
Biotechnology
The US Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation to NS-051/NCNP-04, which is being developed for the treatment of Duchenne muscular dystrophy (DMD) by Japanese drugmaker Nippon Shinyaku. 24 January 2025
Biotechnology
Danish biotech Genmab (CPH: GMAB) today announced it has named Leslie Amendola senior vice president and general manager of its US business. 24 January 2025
Biotechnology
Sino-American oncology company Shenzhen TargetRx has successfully completed its Series C financing, raising $50 million. 23 January 2025
Pharmaceutical
Chicago-based drug major AbbVie and privately-held San Diego firm Neomorph have announced a collaboration and option-to-license agreement to develop novel molecular glue degraders for multiple targets across oncology and immunology. 23 January 2025
Biotechnology
Flagship Pioneering, the USA-based bioplatform innovation company, has announced a new collaboration with UK-based healthcare groups. 23 January 2025
Pharmaceutical
Patients For Affordable Drugs, Public Citizen, Social Security Works and other campaigners are to gather in Washington, DC next week with the aim of delivering a message to pharma. 23 January 2025
Pharmaceutical
Competition in the ever-growing market for obesity treatments continues to mount, with positive early data for Hong Kong’s Ascletis Pharma. 23 January 2025
Biotechnology
USA-based healthcare giant Johnson & Johnson has announced the publication of key Phase III data for nipocalimab in The Lancet Neurology. 23 January 2025
Pharmaceutical
An Expert View from Kevin Wild, head of pre-sales at software company Syniti. 23 January 2025
Biotechnology
The US Food and Drug Administration (FDA) has accepted Biogen’s supplemental New Drug Application (sNDA) and the European Medicines Agency (EMA) has validated the application for a higher dose regimen of nusinersen, marketed as Spinraza, for spinal muscular atrophy (SMA). 23 January 2025
Biotechnology
A pair of Chinese biotech companies have filed to list on the Hong Kong Stock Exchange. 23 January 2025
Biotechnology
China-based Kelun-Biotech Biopharmaceutical has received marketing authorization in China from National Medical Products Administration (NMPA) for the programmed cell death ligand 1(PD-L1)-directed innovative humanized monoclonal antibody (MAb) tagitanlimab (formerly KL-A167) used in combination with cisplatin and gemcitabine for the first-line treatment of patients with recurrent or metastatic nasopharyngeal cancer (NPC). 23 January 2025
Pharmaceutical
Regulatory authorities, particularly the US Food and Drug Administration (FDA), have played a crucial role in accelerating and incentivizing the development of innovative treatments through review designations. 23 January 2025
Biotechnology
Xilio Therapeutics has reported initial results from its Phase II trial of vilastobart, an anti-CTLA-4 therapy, in combination with Roche's Tecentriq (atezolizumab). 23 January 2025
Biotechnology
USA-based biotech IMMvention Therapeutix yesterday revealed it has entered into a strategic collaboration and license agreement with Novo Nordisk to co-develop oral therapies for sickle cell disease (SCD) and other chronic conditions. 23 January 2025
Biotechnology
US genetic meds company MeiraGTx Holdings yesterday revealed that the US Food and Drug Administration (FDA) has granted the company Rare Pediatric Disease (RPD) designation to its AAV8-RK-RetGC program for the treatment of patients with Leber congenital amaurosis due to GUCY2D mutations (LCA1). 23 January 2025
Pharmaceutical
Johnson & Johnson presented its financial results for the last quarter of 2024, the year as a whole, and its guidance for 2025. 22 January 2025
Pharmaceutical
The new US President has repealed an executive order from October 2023, signed by the Biden administration, that sought to establish rigorous safeguards for artificial intelligence (AI) development. 22 January 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze